WASHINGTON (MedPage Today) — In the midst of a deep economic recession, America’s health insurance companies increased their profits by 56% in 2009, a year that saw 2.7 million people lose their private coverage.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Hoping to curb allergic reactions at restaurants, Massachusetts will become the first state to require food workers to undergo training in preparing safe meals for customers who are allergic to foods such as nuts, milk, and shellfish.
No Comments »
Filed under: General Health News
A mumps outbreak in New York and New Jersey has tripled the annual incidence observed since introduction of the MMR vaccine more than 40 years ago, according to a report from the CDC.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA has approved the antihypertensive olmesartan (Benicar) for use in patients ages six to 16.
No Comments »
Filed under: Pharmacy News
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France’s regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis’ and Debiopharm’s August 2009 [...]
No Comments »
Filed under: Pharmacy News
Our mission is to bring new drug compounds to the marketplace. And we’ve never been in a stronger position to deliver on that promise. We’ve built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer [...]
No Comments »
Filed under: Pharmacy News
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia’s latest clinical results follow two earlier successful phase II studies [...]
No Comments »
Filed under: Pharmacy News
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company’s novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center [...]
No Comments »
Filed under: Pharmacy News
Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.
No Comments »
Filed under: Pharmacy News
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for [...]
No Comments »
Filed under: Pharmacy News
